Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

Another Setback for Gardasil

Posted by Jane Akre
Friday, January 09, 2009 11:58 AM EST
Category: Major Medical, Protecting Your Family
Tags: Gardasil, Merck & Co, FDA and Prescription Drugs, HPV, Cervical Cancer, Genital Warts

Gardasil faces another FDA setback in efforts to prescribe it to older women.

LEARN MORE

 

IMAGE SOURCE: © ©iStockphoto/ girl being vaccinated/ author: pflorendo

 

Merck & Co has had high hopes for its cervical cancer drug, Gardasil.

It aggressively advertised use of the drug after it was approved in 2006, in its “One Less” campaign for use in adolescent and teenage girls.

Merck has lobbied female legislators to introduce state laws to make the vaccine mandatory, largely unsuccessful so far. Merck says it has since dropped lobbying for Gardasil school-requirements and is focused on educating lawmakers.

In its latest push, Merck wants Gardasil to be used by women ages 27 to 45. It is currently approved in women and girls ages 9 to 26.

But the Food and Drug Administration (FDA) is putting that plan on hold until it receives more data from Merck & Co. Merck’s initial application included data from patients collected over two years. The FDA wants to review the final results of a four-year study which are forthcoming with research done and delivered to the FDA by Merck.

This is the second setback for the drug maker over Gardasil.

Last June, the FDA denied Merck’s request to expand the use in older women. About 80 percent of adult women have been exposed to the humanpapilloma virus (HPV), which  causes cervical cancer and genital warts. Their own immune system keeps it in check. Gardasil is less effective after someone has been exposed to the virus.

While the drug had blockbuster potential and strong sales after its 2006 launch, 2008 sales reportedly flattened, partially due to adverse health effects. 

The nonprofit group, Judicial Watch, has made public the FDA’s reports, including 10 deaths since September 2007, and more than 140 serious adverse events following inoculations of the vaccine.

Then there was the news reported in the New England Journal of Medicine in August that suggests the results might not be worth the price of Gardasil. A three shot series costs $350. 

Merck & Co’s latest push is to give Gardasil to males after a study released in November said it might be effective in preventing genital warts and penile cancer.

Projected sales figures for 2009 stand at $1.4 billion to $1.6 billion, reports Reuters. 

Merck & Co shares fell 2 percent in morning trading. #


No Comments

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address

Subscribe

RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes